Edasalonexent（CAT-1004）是一种口服生物可利用的核因子κB（NF-κB）信号通路抑制剂，通过阻断NF-κB的活化发挥抗炎作用，在杜氏肌营养不良等疾病治疗研究中具有应用潜力。

/

-25~-15℃避光保存，有效期3年。

[1] Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639. doi: 10.1002/jcph.842. Epub 2017 Jan 11. PMID: 28074489; PMCID: PMC5412838.

[2] Hammers DW, Sleeper MM, Forbes SC, Coker CC, Jirousek MR, Zimmer M, Walter GA, Sweeney HL. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341. doi: 10.1172/jci.insight.90341. PMID: 28018975; PMCID: PMC5161210.